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Capsule Summary: 
Our proof-of-concept study shows that omalizumab given during the winter respiratory viral 
season can prevent severe exacerbations but only while the drug is being taken.  
 
Key Words: children, immunotherapy, IgE, randomized controlled trial. 
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Severe winter asthma exacerbations may be prevented by omalizumab but no carry 
over effect. 
To the Editor, 
Recurrent severe exacerbations of asthma are associated with decreased lung growth or 
accelerated loss of lung function and add substantially to both the cost and morbidity 
associated with asthma. Risk factors for acute exacerbations include previous acute 
exacerbation, young age, poorly controlled asthma, and, in particular, viral respiratory 
infections. Exacerbations in school-aged children have been associated with  sensitisation to 
aeroallergens, particularly severe exacerbations requiring hospitalization, where up to 90% of 
the affected group is atopic and has a viral infection1.   This apparent co-morbidity is the 
subject of ongoing controversy, but recent studies have provided a plausible and testable 
hypothesis which may explain how atopy contributes to the exacerbation process1. Notably, 
that cross-linking of high affinity IgE receptors (FcεR1) on plasmacytoid dendritic cells2and 
myeloid dendritic cells3 of atopics at airway mucosal infection sites, leading respectively to 
attenuation of Type 1 IFN production and enhancement of pro-inflammatory Th2 cytokine 
production, markedly amplifies local inflammation1-3. This amplification process is IgE-
dependent, and hence blocking of available IgE during winter periods of high risk for viral 
infection may protect against these events1. 
Several recent studies support this general concept.  Firstly, the addition of omalizumab, a 
humanised IgG1 monoclonal anti-IgE antibody, to regular inhaled steroids given to children 
with inadequately controlled atopic asthma, reduced their exacerbations by 43% compared to 
placebo4. Secondly, in the Inner-City Asthma Study the addition of omalizumab to 
guidelines-based therapy reduced the number of days with asthma symptoms, and reduced 
the proportion of study participants having one or more exacerbation from 48.8% to 30.3% 
across the 1 year treatment period. The strongest effect was on exacerbations occurring 
during the fall virus season5. Thirdly, short-term pre-seasonal treatment with omalizumab 
blunted the ensuing fall asthma “epidemic” in atopic school children6. 
An important question arising from these observations is whether reducing virus-associated 
exacerbations in a single season is a sufficient “circuit-breaker” to decelerate progression of 
asthma towards chronicity. To test this, we conducted a double-blind randomised controlled 
2-year pilot study of 27 children (58 screened), aged 6-15 years (mean 11.45±2.99), 14 
males, with a history of a severe exacerbation of asthma in the previous winter (clinical trial 
registration ACTRN12611001106921). Details of the study protocol and methods are shown 
in the online data repository. All children were sensitized to aeroallergens and had asthma for 
a mean of 7.7 (SD4.5) years. Demographic and clinical characteristics are shown in the table, 
with no important differences between groups. Children received omalizumab (n=14) or 
placebo (n=13) injections every 2 (n=15) to 4 (n=12) weeks based on their baseline total IgE, 
as per manufacture’s recommendations, for 5 months to cover the winter viral season in 
Australia. Severe and moderate asthma exacerbations were defined according to the 
ATS/ERS consensus statement on asthma control7. Children were assessed at the time of each 
injection, at the end of the treatment period and then followed, without treatment, through the 
following year (follow-up period). The study schedule and procedures are shown in the 
online data repository. Primary comparisons between groups were made using negative 
binomial regression. 
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Twenty five children completed the treatment and 22 completed the follow-up. Despite the 
small number, significantly fewer severe asthma exacerbations were seen in children treated 
with omalizumab (n=1) than placebo (n=6), with an incident rate in the placebo group 10.8 
greater than that in the omalizumab group (p=0.024).  The time to first severe exacerbation 
was longer in those receiving omalizumab [mean 240.5 (SD=87.9) days v 107.0 (115.9) days, 
p=0.08] (figure). There were no differences in the number of moderate exacerbations 
[incident rate1.24, p=0.58], the time to first moderate exacerbation [177.3 (140.6) days v 87.3 
(89.6) p=0.91] or in lower respiratory illnesses [incident rate 1.52, p=0.11] between the study 
groups. The reduction in severe exacerbations was not seen during the follow-up period 
[incident rate 0.45, p=0.45]. No statistically significant or clinically important changes were 
seen in lung function. We attempted to perform methacholine challenges at baseline, 
following treatment and after follow-up but many of the children were not able to perform the 
test due to low baseline lung function. In those where able to participate (n=15) there were no 
differences in PD20 between the groups at any time point nor any trend for reduction in 
methacholine responsiveness in either group. 
The small numbers of children in this study means that our results must be treated with 
caution, as our pre-study sample size calculations suggested that we needed 42 subjects per 
group to have 80% power to detect a 50% reduction in severe exacerbations with 
omalizumab. In addition, the placebo group were taking higher doses of ICS raising the 
possibility of less-well controlled asthma. However, they had a similar number of severe 
exacerbations in the previous 12 months (Table). Nevertheless, taken in conjunction with 
similar recent findings on omalizumab-mediated blunting of the “fall’ epidemics in 
susceptible children6, they do support the general concept of targeted disruption of atopy-
associated pathways during periods of high risk as an asthma treatment strategy.  Our 
findings of a lack of carryover of the protective effect of omalizumab treatment in a single 
virus season into the subsequent year leaves open the question of whether omalizumab can 
halt disease progression.  This important question needs to be addressed in subsequent 
prospective studies. 
This letter is accompanied by an online data supplement available at ….. 
Peter D Sly AO, MD, DSc, Children’s Health Queensland and Child Health Research Centre, 
University of Queensland, Brisbane, Australia 
Julie Varghese, BHMS, PGDCTM, Child Health Research Centre, University of Queensland, 
Brisbane, Australia 
Farhana Noor, BSc (App Stats) MDS, Child Health Research Centre, University of 
Queensland, Brisbane, Australia 
Mimi LK Tang MBBS, PhD, Murdoch Children’s Research Institute,  University of 
Melbourne, and Royal Children’s Hospital, Melbourne, Australia 
Ingrid Laing, PhD, Telethon Kids Institute and School of Paediatric and Child Health, 
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Steve Oo, MBBS, School of Paediatric and Child Health, University of Western Australia, 
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Table: Baseline demographic and clinical characteristics of randomized subjects 
 Active (n=14) Placebo (n=13) p* 
Age years (mean±SD) 11.51 ±2.94  11.40 ±3.15 0.92 
Sex male (%) 54 46 0.84 
Total IgE kU/L (mean±SD) 474.57 ± 248.76 372.80± 287.21 0.31 
Lung function** 
• FVC Z (mean±SD) 
• FEV1 Z (mean±SD) 
• FEV1 / FVC Z (mean±SD) 
 
-0.13 ± 0.86 
-1.06 ± 1.25 
-1.38 ± 1.36 
 
-0.15 ± 1.02 
-1.17 ± 1.00 
-1.55 ± 1.31 
 
0.85 
0.89 
0.70 
Asthma control test (mean±SD) 16 ± 5.8 17 ± 4.2 0.85 
Inhaled corticosteroid dose µg 
BDP equivalent (mean±SD) 
705.56 ±531.89 1088.46±666.51 0.08 
Length of asthma (mean±SD) 7.9 ± 5.18 7.5 ± 3.75 0.78 
Asthma exacerbations previous 12 
months, median (25%-75%) 
2.5 (1.75 – 3.00) 2.0 (1.50 – 3.00) 0.83 
Family history of asthma 11 10 0.99 
Failed to complete study    
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• Lost to follow-up 2 2 
• Withdrew consent 0 1  
• Withdrew due to AEs 1 0  
*Wilcoxon rank-sum test was employed for continuous variables and Chi-square test for categorical variables,  **Z-scores 
calculated using GLI calculator. 
 
Figure 1: Time to first severe exacerbation. The proportion of the active (n=14) and 
placebo (n=13) groups “surviving” without acute severe exacerbation is shown at each visit 
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ONLINE DATA REPOSITORY 
Severe winter asthma exacerbations may be prevented by omalizumab but no carry 
over effect. 
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A phase 3, multi-centre, double blind, Randomised, placebo-controlled, study testing the 
Efficacy of winter only treatment with omaLizumab for the reduction of Asthma 
eXacerbations in children aged 6 to 15 years  
Clinical Sites: Royal Children’s Hospital, Brisbane (Site Investigator: Prof Peter Sly); Royal 
Children’s Hospital, Melbourne (Site Investigator: Prof Mimi Tang); Princess Margaret 
Hospital, Perth (Site Investigator: Prof Peter LeSouef) 
The study population included children aged 6 to 15 years with asthma prone to acute 
exacerbations. 96 children will be randomised. Randomisation occurred in blocks, stratified 
by study site based on predetermined block sizes. 
Inclusion criteria 
Participants who meet all of the following criteria were eligible for enrolment:  
1. Children of either sex, aged 6 to 15 years, with current asthma 
2. Admission to a hospital emergency department in the previous winter season for acute 
exacerbation of asthma, as defined by the ATS/ERS statement on asthma control and 
exacerbations 
3. Positive skin prick tests to aeroallergens 
4. Atopic family history 
5. Written informed consent signed and dated by parent/legal guardian according to local 
regulations 
 
Exclusion criteria 
Participants who meet any of these criteria were not eligible for enrolment: 
1. Hypersensitivity to omalizumab 
2. Treatment with omalizumab within 30 days prior to screening 
3. Prolonged high dose oral steroids 
4. Participation in another randomized controlled trial within the 3 months preceding 
inclusion in this study 
5. A significant medical disease or condition other than asthma likely to interfere with the 
child’s ability to complete the entire protocol. 
 
Study Design 
The study was conducted as a multi-centre, double-blind, randomized, placebo-controlled 
study testing the efficacy of omalizumab treatment during winter for the reduction of asthma 
exacerbations in children with exacerbation-prone asthma. Children identified from 
emergency department records as having an acute asthma exacerbation during the previous 
winter viral season and found eligible in the screening visit were randomized into two groups. 
The “Active” group received omalizumab every two or four weeks for five months, timed to 
cover the winter viral season (April/May to September/October). The “Control” group 
received identical placebo. Omalizumab was administered by subcutaneous injection every 2 
or 4 weeks based on baseline serum total IgE (IU/ml), measured before the start of treatment, 
and body weight (kg). The dosing regimen is shown in Table 1 (1). All children also received 
standard asthma therapy as prescribed by their treating paediatrician. 
Primary efficacy endpoint 
The proportion of children with acute asthma exacerbations as defined by the ATS/ERS 
statement on asthma control and exacerbations (2) during treatment period, i.e. from Visit 1 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
3 
 
(first dosing) to visit 6 (one month after last dose). Severe and moderate exacerbations were 
treated separately. 
Secondary efficacy endpoints 
• The proportion of viral respiratory infections that result in lower airway symptoms 
during the treatment period, i.e. from Visit 1 (first dosing) to visit 6 (one month after 
last dose).  
• Lung function and airway responsiveness over the follow up period, i.e. from Visit 6 
(one month after last dose) until visit 18 (12 months after last dose). 
Safety endpoints 
• Urticarial or anaphylactic reaction to omalizumab. 
• Treatment-related adverse events. 
• Haematology and clinical chemistry. 
 
Data Safety Monitoring Board 
Safety data were presented by group in a blinded fashion to the Data Safety and Monitoring 
Board (DSMB) at scheduled DSMB meetings during the trial. The DSMB had the authority 
to request un-blinded data if necessary. The DSMB had the authority to recommend that 
enrolment or study treatment be discontinued for the safety of participants. While the DSMB 
were to examine all safety data, they were requested to pay particular attention to the number 
of episodes of anaphylaxis.  
Study procedures 
Procedures conducted as a part of the participant’s routine clinical management and obtained 
prior to informed consent were allowed to be used for screening purposes or assessing 
eligibility criteria. However, the procedure must have met the protocol-defined criteria and 
have been performed within the timelines permitted by the protocol. 
 
Informed consent 
A signed, written informed consent was obtained from the participant’s parent/legal guardian 
prior to any study-specific assessments or procedures.  
 
Asthma control 
Childhood asthma control test for children 11 years and younger, and the asthma control test 
for children 12 years and older was performed at visits 0, 6 and 18 to document asthma 
control. 
Analysis sample 
The following groups of participants will define samples for endpoint analysis: 
• Intention to Treat (ITT) sample – All participants who are randomized and have 
evaluable data for the endpoint under investigation. Participants will be analyzed in the 
group to which they were randomized, regardless of compliance to their allocated 
treatment. The number of participants who have evaluable data may differ for each 
endpoint being investigated.  
• Safety sample - All participants who take at least one dose of the investigational 
product. 
Statistical Analysis 
The primary data on asthma exacerbations and lower respiratory tract infections were not 
normally distributed and did not fit with a Poisson distribution. As the date were over-
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dispersed, i.e. the variance was greater than the mean, negative binomial regression was used 
for these primary analyses. Kaplan-Meyer survival analyses were used to examine the time to 
first exacerbation, with the log rank test used to test the difference in survival between the 
treatment groups. Group differences in demographic data were tested using Wilcoxon rank-
sum test for continuous variables and Chi-square test for categorical variables. 
 
Schedule of study assessments and procedures 
A schedule of study visits, procedures and assessments is shown in Table 2. 
 
Results 
 
Asthma control test (ACT) scores 
There were no differences in the ACT scores between groups at baseline [omalizumab 
mean=16 (SD = 5.8) v placebo 17 (4.2), p=0.85], at the end of the treatment period [20 (3.6) 
v 20 (3.1), p=0.90] or at the end of the follow-up period [20 (5.5) v 22 (1.7), p=0.10]. 
 
Exacerbations and LRTI 
Treatment period 
• Severe exacerbations: incident rate 10.83, p=0.024 
• Moderate exacerbations: incident rate 1.24, p=0.58 
• LRTI: incident rate 1.52, p=0.11 
Follow-up period 
• Severe exacerbations: incident rate 0.45, p=0.10 
• Moderate exacerbations: incident rate 0.53, p=0.53 
• LRTI: incident rate 1.05, p=0.86 
 
 
 
References 
1. Katelaris C, Douglass J, Gibson P, Heddle R, Rimmer J, Ruffin R, et al. Omalizumab: 
recommendations for use in the Australasian context. Sydney: Thoracic Society of 
Australia and New Zealand, 2009. 
2. Reddel H, Taylor D, Bateman E, Bouler L-P, Boushey H, Busse W, et al. An official 
American Thoracic Society / European Respiratory Society statement: asthma control and 
exacerbations. Am J Respir Crit Care Med 2009; 180:59-99. 
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Table 1: Paediatric dosing schedule for omalizumab (mg) per four week or two 
week interval 
 
Dosing 
Interval 
Baseline IgE 
(IU/ml) 
Body weight (kg) 
>20-
25 
>25-
30 
>30-
40 
>40-
50 
>50-
60 
>60-
70 
>70-
80 
>80-
90 
>90-
125 
>125-
150 
Q4 
weeks 
≥30-100 75 75 75 150 150 150 150 150 300 300 
>100-200 150 150 150 300 300 300 300 300 225 300 
>200-300 150 150 225 300 300 225 225 225 300 375 
>300-400 225 225 300 225 225 225 300 300 
 
>400-500 225 300 225 225 300 300 375 375 
>500-600 300 300 225 300 300 375  
 
>600-700 300 225 225 300 375  
DO NOT 
ADMINISTER Q2 
weeks 
>700-800 225 225 300 375 
 
 
>800-900 225 225 300 375 
>900-
1,000 
225 300 375 
 
 
>1,000-
1,100 
225 300 375 
>1,100-
1,200 
300 300 
  
>1,200-
1,300 
300 375 
 
 
 
 
 
 
.
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Table 2: Schedule of Assessments and Procedures 
Study period Screening Treatment Follow-up 
RTI UV 
Visit 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 
Week 8w to -1d 0 4 8 12 16 20 24 28 32 36 40 44 48 52 56 60 64 72   
Visit window   ± 3 
days 
± 3 
days 
± 3 
days 
± 3 
 
± 3 
days 
± 5 
days 
± 5 
days 
± 7 
days 
± 5 
days 
± 5 
days 
± 7 
days 
± 5 
days 
± 5 
days 
± 7 
days 
± 5 
days 
± 5 
days 
± 7 
days 
Telephone call        x x  x x  x x  x x    
Informed consent x                     
Review eligibility criteria x x                    
Randomisation  x                    
History x                     
Physical examination x x x x x x x   x   x   x   x  x 
Drug delivery  x x x x x                
Skin prick test x                     
Nasal wash x  x x x x x   x   x   x   x  x* 
Nasal swab                    x**  
Posterior palatal swab x      x            x   
Lung function / 
Methacholine challenge  x     x            x   
Pregnancy test x x x x x x x   x   x   x   x   
Asthma control test x      x            x   
Dispense diary card  x x x x x x   x   x   x      
Diary card review   x x x x x   x   x   x   x x  
Dispense rescue medication  x                    
Review rescue medication 
procedures   x x x x                
Collect rescue medication       x               
Asthma severity score                     x* 
Blood collection x      x            x  x* 
Adverse event review  x x x x x x x x x x x x x x x x x x  x 
Concomitant medication 
review x x x x x x x x x x x x x x x x x x x  x 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
7 
 
RTI=Respiratory tract infections; UV=unscheduled visit; *When presenting to A&E for acute asthma exacerbation; **Respiratory tract infections only. 
